Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study

Authors:
  • MBMark F. Brady
    Mark F. Brady
  • KDKathleen M. Darcy
    Kathleen M. Darcy
  • WMWilliam P. McGuire
    William P. McGuire
  • PEPamela Edmonds
    Pamela Edmonds
  • MPMichael L. Pearl
    Michael L. Pearl
  • IIIouri Ivanov
    Iouri Ivanov
  • KTKrishnansu S. Tewari
    Krishnansu S. Tewari
  • RMRobert S. Mannel
    Robert S. Mannel
  • KZKristine Zanotti
    Kristine Zanotti

Abstract
No abstract available

This publication has 27 references indexed in Scilit: